Terns Pharmaceuticals, Inc. (TERN) News
Filter TERN News Items
TERN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TERN News Highlights
- For TERN, its 30 day story count is now at 4.
- Over the past 28 days, the trend for TERN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DUET, THR and TOP are the most mentioned tickers in articles about TERN.
Latest TERN News From Around the Web
Below are the latest news stories about TERNS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TERN as an investment opportunity.
Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology ConferenceFOSTER CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023 at 10:10 a.m. |
The Quant Trading System Picking Stocks That Soar 300%In the latter half of 2022, the S&P dropped 7%. |
Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology ConferenceFOSTER CITY, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will participate in a fireside chat at the B. Riley Securities 3rd Annual Oncology Conference on Wednesday, January 18, 2023 at 2:30 p.m. ET |
Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare ConferencePlans to advance diverse pipeline of five disclosed programs in oncology and metabolic diseases |
$2.4 Million Bet On Duolingo? Check Out These 3 Stocks Insiders Are BuyingAlthough US stocks closed lower on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company''s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga''s insider transactions platform. Terns Pharmaceuticals The Trade: Terns Pharmaceuticals, Inc. (NASDAQ: … Full story available on Benzinga.com |
Hedge Fund and Insider Trading News: Donald Sussman, Sanjay Shah, Scott Bessent, Morgan Creek Capital, Glimpse Group Inc (VRAR), Terns Pharmaceuticals, Inc. (TERN), and MoreHedge Funder Donald Sussman Sells Waterfront Fort Lauderdale Lot for $17M (The Real Deal) Hedge funder Donald Sussman sold a waterfront lot in Fort Lauderdale for $17 million to a Texas-based aerospace executive in an off-market deal. The Laguna Property Trust sold the 0.7-acre lot at 2401 Laguna Drive to Arrowhead Hillcountry Investments, a Texas […] |
$5.5 Million Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are BuyingAlthough US stocks closed higher on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company''s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga''s insider transactions platform. Terns Pharmaceuticals The Trade: Terns Pharmaceuticals, Inc. (NASDAQ: Full story available on Benzinga.com |
Tern (NASDAQ:TERN) Stock: Insiders Buy Shares Worth $11MTwo corporate insiders at Terns Pharmaceuticals (NASDAQ:TERN) disclosed having purchased TERN stock worth $11 million. The clinical-stage biopharma… |
Terns Announces Closing of Public Offering of Shares of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesFOSTER CITY, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced the closing of its previously announced underwritten public offering of 11,902,500 shares of its common stock, including 1,552,500 shares sold pursuant to t |
Terns Pharmaceuticals, OceanPal among premarket losers'' packCelyad Oncology CYAD -29% as blood cancer drug CYAD-211 gets axed in strategic review.OceanPal (OP) -24%.Applied UV (AUVI) -8%.Cosmos Holdings (COSM) -8%.Terns… |